Allogeneic cell therapeutics development
Not specified
ResearchActive
Key Facts
About SaxoCell
SaxoCell is a privately held, non-profit consortium founded in 2001 and based in Dresden, Germany. It operates as a regional innovation cluster uniting academic, clinical, and industrial partners to advance the field of cell and gene therapy. Its core mission is to develop more affordable and accessible allogeneic (off-the-shelf) cell therapeutics through research projects focused on novel applications, production methods, and automation. The cluster is pre-revenue, acting as a collaborative R&D and technology transfer engine rather than a single commercial biotech entity.
View full company profileOther Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |